Audentes Therapeutics, Inc. (BOLD) financial statements (2020 and earlier)

Company profile

Business Address 600 CALIFORNIA ST., 17TH FLOOR
SAN FRANCISCO, CA 94108
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 414134105
Cash and cash equivalents 1443936
Short-term investments 2709569
Restricted cash and investments  01
Other undisclosed current assets 533
Total current assets: 420137108
Noncurrent Assets
Property, plant and equipment 322419
Intangible assets, net (including goodwill) 121212
Goodwill 444
Intangible assets, net (excluding goodwill) 888
Restricted cash and investments 443
Other noncurrent assets 520
Total noncurrent assets: 534234
TOTAL ASSETS: 473179142
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 211312
Accounts payable 842
Accrued liabilities 13910
Deferred rent credit 0
Business combination, contingent consideration, liability 25 
Deferred revenue and credits00
Total current liabilities: 241813
Noncurrent Liabilities
Liabilities, other than long-term debt 6910
Deferred revenue and credits32
Deferred rent credit 5
Asset retirement obligations 011
Deferred tax liabilities, net113
Business combination, contingent consideration, liability  54
Other undisclosed noncurrent liabilities  (5) 
Total noncurrent liabilities: 6410
Total liabilities: 302223
Stockholders' equity
Stockholders' equity attributable to parent 443157119
Additional paid in capital 762347220
Accumulated other comprehensive loss (0)(0)(0)
Accumulated deficit (319)(191)(100)
Total stockholders' equity: 443157119
TOTAL LIABILITIES AND EQUITY: 473179142

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
Operating expenses (134)(93)(60)
Operating loss: (134)(93)(60)
Nonoperating income 610
Investment income, nonoperating 610
Other nonoperating expense (0)(0)(0)
Loss from continuing operations before income taxes: (129)(92)(60)
Income tax benefit  2 
Net loss available to common stockholders, diluted: (129)(90)(60)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
Net loss: (129)(90)(60)
Other comprehensive loss   (0)
Comprehensive loss: (129)(90)(60)
Other undisclosed comprehensive loss, net of tax, attributable to parent (0)(0) 
Comprehensive loss, net of tax, attributable to parent: (129)(90)(60)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: